Koppen Laura M, Whitaker Andrea, Rosene Audrey, Beckett Robert D
1 University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA.
2 University Health System, San Antonio, TX, USA.
J Evid Based Complementary Altern Med. 2017 Oct;22(4):956-968. doi: 10.1177/2156587216687695. Epub 2017 Jan 16.
The objective of this review is to identify, summarize, and evaluate clinical trials of berberine for the treatment of hyperlipidemia and other dyslipidemias. A literature search for randomized, controlled trials of berberine that assessed at least 2 lipid values as endpoints resulted in identification of 12 articles that met criteria. The majority of evaluated articles consistently suggest that berberine has a beneficial effect on low-density lipoprotein (reductions ranging from approximately 20 to 50 mg/dL) and triglycerides (reductions ranging from approximately 25 to 55 mg/dL). Common study limitations included lack of reporting of precision in their endpoints, description of blinding, transparency in flow of patients, and reporting of baseline concomitant medications. Berberine could serve as an alternative for patients who are intolerant to statins, patients resistant to starting statin therapy but who are open to alternative treatments, and for low-risk patients not indicated for statin therapy.
本综述的目的是识别、总结和评估黄连素治疗高脂血症及其他血脂异常的临床试验。对评估至少2项血脂值作为终点的黄连素随机对照试验进行文献检索,结果确定了12篇符合标准的文章。大多数评估文章一致表明,黄连素对低密度脂蛋白(降低幅度约为20至50mg/dL)和甘油三酯(降低幅度约为25至55mg/dL)有有益作用。常见的研究局限性包括终点精确性报告缺失、盲法描述、患者流程透明度以及基线合并用药报告。黄连素可作为不耐受他汀类药物的患者、对开始他汀类治疗有抵抗但愿意接受替代治疗的患者以及未被指明适用他汀类治疗的低风险患者的替代药物。